Loading company…
Pharmacyclics develops and commercializes cancer therapies, including ibrutinib.
Founded in 1991 and based in Sunnyvale, Pharmacyclics develops therapies for blood cancers and other malignancies. Its products include ibrutinib, a treatment approved for indications including chronic lymphocytic leukemia and mantle cell lymphoma. AbbVie acquired the company in May 2015.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in